Published by Frank Prenesti on 10th June 2022
(Sharecast News) - GlaxoSmithKline said its vaccine for respiratory virus had shown "statistically significant" and clinically meaningful efficacy in adults aged 60 years and above in a phase 3 trial.
URL: http://www.digitallook.com/dl/news/story/32740017/...